SAB Biotherapeutics (SABS) Competitors

SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.

Do institutionals and insiders believe in SABS or FBIO?

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 26.5% of SAB Biotherapeutics shares are held by insiders. Comparatively, 33.4% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more volatility & risk, SABS or FBIO?

SAB Biotherapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Do analysts prefer SABS or FBIO?

SAB Biotherapeutics currently has a consensus price target of $12.20, indicating a potential upside of 555.91%. Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 1,113.87%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer SABS or FBIO?

Fortress Biotech received 295 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 84.62% of users gave SAB Biotherapeutics an outperform vote while only 63.69% of users gave Fortress Biotech an outperform vote.

Company	Underperform	Outperform
SAB Biotherapeutics	Outperform Votes 33 84.62%	Underperform Votes 6 15.38%
Fortress Biotech	Outperform Votes 328 63.69%	Underperform Votes 187 36.31%

Does the media favor SABS or FBIO?

In the previous week, SAB Biotherapeutics had 7 more articles in the media than Fortress Biotech. MarketBeat recorded 10 mentions for SAB Biotherapeutics and 3 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 0.74 beat Fortress Biotech's score of -0.22 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings and valuation, SABS or FBIO?

SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$2.24M	7.72	-$42.19M	-$3.70	-0.50
Fortress Biotech	$57.78M	0.89	-$60.64M	-$2.23	-0.78

Is SABS or FBIO more profitable?

Fortress Biotech has a net margin of -84.53% compared to SAB Biotherapeutics' net margin of -1,450.14%. Fortress Biotech's return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%
Fortress Biotech	-84.53%	N/A	-34.93%

Summary

Fortress Biotech beats SAB Biotherapeutics on 10 of the 17 factors compared between the two stocks.